H.C. Wainwright Maintains Buy on QTTB Q32 Bio Inc. March 2026

H.C. Wainwright maintained a Buy rating on Q32 Bio Inc. (QTTB) on March 10, 2026. The QTTB analyst rating reinforces expectations that 2026 clinical data could drive value. We note the firm reiterated confidence without issuing a new price target. At report time the stock moved -0.17% ($-0.01) on the note. This concise update sets the tone for investors watching Q32 Bio ahead of key catalysts.